Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Launay-Vacher

Showing results (11-20 of 126) with videos related to

Pageof 13
Sort By:
Clinical Pharmacokinetics|March 15, 2005
Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failureVincent Launay-Vacher, Hassane Izzedine, Gilbert Deray
AIDS (London, England)|March 15, 2005
Renal tubular transporters and antiviral drugs: an updateHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
Kidney International|October 22, 2004
Using the right MDRD equationVincent Launay-Vacher, Hassane Izzedine, Gilbert Deray
La Revue Du Praticien|March 8, 2006
[Medication use in older patients with chronic renal failure]Alain Baumelou, Vincent Launay Vacher, Marc Verny
International Journal of Cardiology|March 1, 2006
Abnormal blood pressure circadian rhythm: a target organ damage?Hassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 30, 2005
Antiviral drug-induced nephrotoxicityHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
Nephrologie & Therapeutique|October 11, 2018
[Non-iodinated contrast media nephrotoxicity]Nicolas Janus, Vincent Launay-Vacher, Gilbert Deray
International Journal of Cardiology|April 30, 2005
Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patientsVincent Launay-Vacher, Hassane Izzedine, Gilbert Deray
The American Journal of Medicine|February 19, 2004
Topiramate-induced renal tubular acidosisHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
Kidney International|June 16, 2005
Antiretroviral drugs and the kidney: further precisionsHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
Pageof 13

Showing results (11-20 of 126) with videos related to

Sort By:
Pageof 13
Clinical Pharmacokinetics|March 15, 2005
Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failureVincent Launay-Vacher, Hassane Izzedine, Gilbert Deray
AIDS (London, England)|March 15, 2005
Renal tubular transporters and antiviral drugs: an updateHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
Kidney International|October 22, 2004
Using the right MDRD equationVincent Launay-Vacher, Hassane Izzedine, Gilbert Deray
La Revue Du Praticien|March 8, 2006
[Medication use in older patients with chronic renal failure]Alain Baumelou, Vincent Launay Vacher, Marc Verny
International Journal of Cardiology|March 1, 2006
Abnormal blood pressure circadian rhythm: a target organ damage?Hassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|April 30, 2005
Antiviral drug-induced nephrotoxicityHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
Nephrologie & Therapeutique|October 11, 2018
[Non-iodinated contrast media nephrotoxicity]Nicolas Janus, Vincent Launay-Vacher, Gilbert Deray
International Journal of Cardiology|April 30, 2005
Statins' dosage in patients with renal failure and cyclosporine drug-drug interactions in transplant recipient patientsVincent Launay-Vacher, Hassane Izzedine, Gilbert Deray
The American Journal of Medicine|February 19, 2004
Topiramate-induced renal tubular acidosisHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
Kidney International|June 16, 2005
Antiretroviral drugs and the kidney: further precisionsHassane Izzedine, Vincent Launay-Vacher, Gilbert Deray
Pageof 13